TrialHaematologica2018

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Ramy Rahmé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.